Dual-triggered drug-release vehicles for synergistic cancer therapy
Journal
Colloids and Surfaces B: Biointerfaces
Journal Volume
173
Pages
788-797
Date Issued
2019
Author(s)
Abstract
Cancer is a complex and tenacious disease. Drug-delivery systems in combination with multimodal therapy strategies are very promising candidates for cancer theranostic applications. In this study, a new drug-delivery vehicle that combine human serum albumin (HSA)- and poly(sodium 4-styrenesulfonate) (PSS)-coated gold nanorod nanoparticles(GNR/PSS/HSA NPs) was developed for synergistic cancer therapy. Doxorubicin (DOX) was loaded onto GNR/PSS/HSA NPs, by electrostatic and hydrophobic forces, to create multimodal DOX@GNR/PSS/HSA NPs. DOX@GNR/PSS/HSA NPs were found to be highly biocompatible and stable in physiological solutions. Furthermore, GNR/PSS/HSA NPs with or without DOX were designed to exhibit strong absorbance in the near-infrared region and high photothermal conversion efficiency. Therefore, bimodal DOX release from DOX@GNR/PSS/HSA NPs could be triggered by an acidic pH and by near-infrared irradiation after NPs preferentially accumulated at tumor sites, leading to a significant chemotherapeutic effect. Moreover, DOX@GNR/PSS/HSA NPs were designed to be applied during chemo- and photo-thermal combination therapy and exhibited a synergistic anticancer effect that was superior to the effect of monotherapy, from both in vitro and in vivo results. These results suggest that DOX@GNR/PSS/HSA NPs are a strong candidate for a nanoplatform for future antitumor therapeutic strategies. ? 2018
SDGs
Other Subjects
Biocompatibility; Body fluids; Chemotherapy; Diseases; Drug products; Gold coatings; Gold nanoparticles; Infrared devices; Nanoribbons; Nanorods; Oncology; Targeted drug delivery; Controlled drug release; Gold nanorod; Human serum albumins; Photothermal conversion efficiencies; Photothermal therapy; Physiological solution; Polysodium 4-styrenesulfonate; Triggered drug release; Controlled drug delivery; doxorubicin; gold nanorod; human serum albumin; polystyrenesulfonate sodium; antineoplastic antibiotic; doxorubicin; gold; human serum albumin; nanotube; polymer; styrenesulfonic acid polymer; sulfonic acid derivative; adsorption; animal experiment; animal model; antineoplastic activity; aqueous solution; Article; body weight loss; cancer chemotherapy; cancer inhibition; cell viability; coated particle; concentration response; controlled drug release; controlled study; drug cytotoxicity; drug delivery system; drug solubility; endosome; female; Fourier transform infrared spectroscopy; HeLa cell line; human; human cell; hydrophilicity; hydrophobicity; in vitro study; in vivo study; internalization; lysosome; mouse; nanopharmaceutics; nonhuman; particle size; pH; photothermal therapy; priority journal; static electricity; surface charge; temperature; tumor growth; tumor volume; uterine cervix cancer; zeta potential; animal; chemistry; delayed release formulation; drug formulation; drug release; drug screening; infrared radiation; low level laser therapy; metabolism; molecularly targeted therapy; multimodality cancer therapy; neoplasm; nude mouse; procedures; subcutaneous drug administration; Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Delayed-Action Preparations; Doxorubicin; Drug Compounding; Drug Liberation; Female; Gold; HeLa Cells; Humans; Hydrogen-Ion Concentration; Infrared Rays; Injections, Subcutaneous; Low-Level Light Therapy; Mice; Mice, Nude; Molecular Targeted Therapy; Nanotubes; Neoplasms; Polymers; Serum Albumin, Human; Sulfonic Acids; Xenograft Model Antitumor Assays
Type
journal article